The role of RANK ligand/osteoprotegerin in rheumatoid arthritis
Open Access
- 8 March 2012
- journal article
- research article
- Published by SAGE Publications in Therapeutic Advances in Musculoskeletal Disease
- Vol. 4 (4), 225-233
- https://doi.org/10.1177/1759720x12438080
Abstract
In the complex system of bone remodeling, the receptor activator of nuclear factor κB ligand (RANKL)/osteoprotegerin (OPG) pathway is the coupling factor between bone formation and bone resorption. RANKL binds to the RANK receptor of pre-osteoclasts and mature osteoclasts and stimulates their activation and differentiation. The production of RANKL/OPG by osteoblasts is influenced by hormones, growth factors and cytokines, which each have a different effect on the production of RANKL and OPG. Ultimately, the balance between RANKL and OPG determines the degree of proliferation and activity of the osteoclasts. In rheumatoid arthritis (RA), bone erosions are the result of osteoclastic bone resorption at the sites of synovitis, where RANKL expression is also found. Furthermore, magnetic resonance imaging (MRI) bone edema in RA indicates the presence of active inflammation within bone and the presence of osteitis, which is also associated with the expression of RANKL. Bone loss has been documented in the cortical and trabecular bone in the joints of the hand of RA patients. Both synovitis and periarticular bone involvement (osteitis and bone loss) are essential components of RA: they occur early in the disease and both are predictive for the occurrence and progression of bone damage. RANKL knockout mice and mice treated with OPG did not develop focal bone loss, in spite of persistent joint inflammation. Inhibition of osteoclasts by denosumab, a humanized antibody that selectively binds RANKL, has revealed in patients with RA that the occurrence of erosions and periarticular bone loss can be halted, however without affecting synovial inflammation. This disconnect between inflammation and bone destruction opens new ways to separately focus treatment on inflammation and osteoclastogenesis for preventing and/or minimizing the connection between joints and subchondral bone and bone marrow.Keywords
This publication has 75 references indexed in Scilit:
- Cytokine mRNA profiling identifies B cells as a major source of RANKL in rheumatoid arthritisAnnals Of The Rheumatic Diseases, 2011
- Molecular biology of the blood-brain and the blood-cerebrospinal fluid barriers: similarities and differencesFluids and Barriers of the CNS, 2011
- Cellular and Molecular Mechanisms of Bone RemodelingJournal of Biological Chemistry, 2010
- Control of RANKL gene expressionBone, 2010
- Treating rheumatoid arthritis to target: recommendations of an international task forceAnnals Of The Rheumatic Diseases, 2010
- Denosumab for Prevention of Fractures in Postmenopausal Women with OsteoporosisThe New England Journal of Medicine, 2009
- Cortical hand bone loss after 1 year in early rheumatoid arthritis predicts radiographic hand joint damage at 5-year and 10-year follow-upAnnals Of The Rheumatic Diseases, 2008
- High-grade MRI bone oedema is common within the surgical field in rheumatoid arthritis patients undergoing joint replacement and is associated with osteitis in subchondral boneAnnals Of The Rheumatic Diseases, 2007
- The stem cell niches in boneJCI Insight, 2006
- Osteoclast differentiation and activationNature, 2003